Latham & Watkins has advised four of the lead investors — Frazier Life Sciences, EQT Life Sciences, Monograph, and Forbion — in RQ Bio’s US$115 million (£85.5 million) Series A financing.
RQ Bio is a private biotechnology company developing long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations.
The Latham team was led by San Diego partner Matthew Bush, with London counsel Samantha Peacock, and associate Louie Gray. Advice was also provided on healthcare and life sciences matters by London partner Lydia Torne, with associate Arun John Mohan; on tax matters by London partner Karl Mah, with associate Allegra Benitah; on employment matters by London partner Sarah Gadd, with associate Venice Ma; and on data and technology matters by London associate Dal Lim.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.